Intratumor microbiota as a novel potential prognostic indicator in mesothelioma.

Cox proportional hazards modelling DEG (differentially expressed gene) analysis Kaplan-Meier bioinformatics functional annotation analysis mesothelioma microbiome microbiota

Journal

Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960

Informations de publication

Date de publication:
2023
Historique:
received: 22 12 2022
accepted: 28 02 2023
medline: 3 4 2023
entrez: 31 3 2023
pubmed: 1 4 2023
Statut: epublish

Résumé

Despite increased attention on immunotherapy, primarily immune checkpoint blockade, as a therapeutic approach for mesothelioma (MMe), its efficacy and tolerability remain questioned. One potential explanation for different responses to immunotherapy is the gut and intratumor microbiota; however, these remain an underexplored facet of MMe. This article highlights the cancer intratumor microbiota as a novel potential prognostic indicator in MMe. TCGA data on 86 MMe patients from cBioPortal underwent bespoke analysis. Median overall survival was used to divide patients into "Low Survivors" and "High Survivors". Comparison of these groups generated Kaplan-Meier survival analysis, differentially expressed genes (DEGs), and identification of differentially abundant microbiome signatures. Decontamination analysis refined the list of signatures, which were validated as an independent prognostic indicator through multiple linear regression modelling and Cox proportional hazards modelling. Finally, functional annotation analysis on the list of DEGs was performed to link the data together. 107 genera signatures were significantly associated with patient survival (positively or negatively), whilst clinical characteristic comparison between the two groups demonstrated that epithelioid histology was more common in "High Survivors" versus biphasic in "Low Survivors". Of the 107 genera, 27 had published articles related to cancer, whilst only one (Klebsiella) had MMe-related published articles. Functional annotation analysis of the DEGs between the two groups highlighted fatty acid metabolism as the most enriched term in "High Survivors", whilst for "Low Survivors" the enriched terms primarily related to cell cycle/division. Linking these ideas and findings together is that the microbiome influences, and is influenced by, lipid metabolism. Finally, to validate the independent prognostic value of the microbiome, multiple linear regression modelling as well as Cox proportional hazards modelling were employed, with both approaches demonstrating that the microbiome was a better prognostic indicator than patient age or stage of the cancer. The findings presented herein, alongside the very limited literature from scoping searches to validate the genera, highlight the microbiome and microbiota as a potentially rich source of fundamental analysis and prognostic value. Further in vitro studies are needed to elucidate the molecular mechanisms and functional links that may lead to altered survival.

Identifiants

pubmed: 36999042
doi: 10.3389/fimmu.2023.1129513
pmc: PMC10043377
doi:

Substances chimiques

MME 78185-58-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1129513

Informations de copyright

Copyright © 2023 Pentimalli, Krstic-Demonacos, Costa, Mutti and Bakker.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Lancet. 2021 Jan 30;397(10272):375-386
pubmed: 33485464
Microbiome. 2022 Mar 3;10(1):38
pubmed: 35241180
Cell Rep. 2021 Sep 28;36(13):109765
pubmed: 34592155
Nat Med. 2019 Mar;25(3):377-388
pubmed: 30842679
Br J Surg. 2021 Jun 22;108(6):709-716
pubmed: 34157083
Breast Cancer Res Treat. 2010 Oct;123(3):725-31
pubmed: 20020197
Semin Cancer Biol. 2022 Nov;86(Pt 3):1-10
pubmed: 35882258
Toxicon. 2021 Jul 15;197:126-135
pubmed: 33901549
J Med Internet Res. 2021 Jul 26;23(7):e27633
pubmed: 34309564
Curr Protoc Bioinformatics. 2016 Jun 20;54:1.30.1-1.30.33
pubmed: 27322403
J Pers Med. 2021 Apr 14;11(4):
pubmed: 33919754
J Geriatr Oncol. 2021 Jul;12(6):985-989
pubmed: 33612452
Antimicrob Agents Chemother. 2007 Feb;51(2):800-1
pubmed: 17145795
Sci Rep. 2021 Apr 12;11(1):7870
pubmed: 33846399
J Chemother. 2022 Apr 12;:1-5
pubmed: 35411826
Nat Protoc. 2009;4(1):44-57
pubmed: 19131956
JAMA Netw Open. 2022 Mar 1;5(3):e221490
pubmed: 35262715
Lancet Oncol. 2022 Jan;23(1):e13
pubmed: 34973223
Breast Cancer Res Treat. 2019 Dec;178(3):493-496
pubmed: 31456069
Ageing Res Rev. 2021 Jul;68:101323
pubmed: 33771720
Acta Oncol. 2021 Oct;60(10):1250-1256
pubmed: 34313510
Recent Results Cancer Res. 2011;189:57-78
pubmed: 21479896
Nucleic Acids Res. 2022 Mar 23;:
pubmed: 35325185
JTO Clin Res Rep. 2022 Jan 12;3(3):100280
pubmed: 35243411
J Med Food. 2013 Dec;16(12):1079-85
pubmed: 24328700
Science. 2020 May 29;368(6494):973-980
pubmed: 32467386
Bioorg Chem. 2022 Feb;119:105517
pubmed: 34861626
Microb Cell Fact. 2022 May 16;21(1):88
pubmed: 35578339
Expert Rev Anticancer Ther. 2017 Sep;17(9):799-814
pubmed: 28724330
BMJ. 2018 Jun 13;361:k2179
pubmed: 29899036
Cancer Discov. 2012 May;2(5):401-4
pubmed: 22588877
Int J Mol Sci. 2022 Aug 12;23(16):
pubmed: 36012262
Int J Mol Sci. 2021 May 22;22(11):
pubmed: 34067485
Proc Natl Acad Sci U S A. 2015 Nov 17;112(46):E6369-78
pubmed: 26578797
Molecules. 2016 Mar 03;21(3):305
pubmed: 26950108
Dtsch Arztebl Int. 2010 Nov;107(44):776-82
pubmed: 21116397
Annu Rev Genet. 2019 Dec 3;53:239-261
pubmed: 31487470
J Clin Nurs. 2002 Nov;11(6):723
pubmed: 12427176
Science. 2015 Nov 27;350(6264):1084-9
pubmed: 26541606
Nature. 2020 Mar;579(7800):567-574
pubmed: 32214244
Cancer Treat Rep. 1985 Oct;69(10):1071-77
pubmed: 4042087
Med Hypotheses. 2014 Nov;83(5):537-40
pubmed: 25262213
Cancer Res. 2015 Jan 15;75(2):264-9
pubmed: 25488749
J Immunother Precis Oncol. 2021 Nov 16;5(1):13-25
pubmed: 35663831
Genome Med. 2022 Jan 25;14(1):9
pubmed: 35078527
J Thorac Dis. 2014 Sep;6(9):E196-7
pubmed: 25276398
Genome Biol. 2018 Aug 24;19(1):123
pubmed: 30143034
Acta Oncol. 2021 Apr;60(4):521-527
pubmed: 33502280
Dis Markers. 2022 Jan 20;2022:7994074
pubmed: 35096207
Eur J Dermatol. 2021 Feb 1;31(1):48-54
pubmed: 33586656
JAMA Oncol. 2022 Jul 1;8(7):1059-1067
pubmed: 35482355
Sci Signal. 2013 Apr 02;6(269):pl1
pubmed: 23550210
Nat Commun. 2019 Apr 3;10(1):1523
pubmed: 30944313
Cell. 2020 Oct 29;183(3):666-683.e17
pubmed: 32991841
Epidemiology. 1990 Jan;1(1):43-6
pubmed: 2081237
Cancer Discov. 2022 Jan;12(1):31-46
pubmed: 35022204
BMJ Case Rep. 2021 Jul 29;14(7):
pubmed: 34326118
J Cell Biochem. 2015 Aug;116(8):1540-52
pubmed: 25757056
Am J Cancer Res. 2018 Sep 01;8(9):1775-1787
pubmed: 30323970
Rev Endocr Metab Disord. 2019 Dec;20(4):461-472
pubmed: 31707624
Cancers (Basel). 2021 Nov 12;13(22):
pubmed: 34830817
J Gastrointest Oncol. 2021 Apr;12(Suppl 1):S216-S229
pubmed: 33968439
Ann Thorac Surg. 2016 May;101(5):1644-5
pubmed: 27106412

Auteurs

Francesca Pentimalli (F)

Department of Medicine and Surgery, LUM University "Giuseppe DeGennaro", Bari, Italy.

Marija Krstic-Demonacos (M)

Biomedical Research Centre, School of Science, Engineering and Environment, University of Salford, Salford, United Kingdom.

Caterina Costa (C)

Cell Biology and Biotherapy Unit, Istituto Nazionale Tumori-Scientific Institute for Research and Care (IRCCS)-Fondazione G. Pascale, Napoli, Italy.

Luciano Mutti (L)

Center for Biotechnology, Sbarro Institute for Cancer Research and Molecular Medicine, College of Science and Technology, Temple University, Philadelphia, PA, United States.
Department of Biotechnological and Applied Clinical Sciences, University of Aquila, L'Aquila, Italy.

Emyr Yosef Bakker (EY)

School of Medicine, University of Central Lancashire, Preston, United Kingdom.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH